Spotlight on NIH Therapeutics for Rare Diseases Program

Most clinical research professionals are familiar with FDA’s Office of Orphan Products Development and the provisions of 21 CFR that facilitate the marketing of new treatments for rare health conditions. A lesser-known NIH program called TRND (Therapeutics for Rare and Neglected Diseases) provides a different kind of support for rare disease research. According to a story on the Genetic Engineering & Biotechnology News website, the program has approved a total of 15 projects and two have moved into clinical testing.

Share This Post